Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.56 |
| ▸ | HPGD | P15428 | 8/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21648250 | 1.00 | RAB9A (0.62) | RAB9AALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL21629625 | 1.00 | RAB9A (0.62) | RAB9AALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL21629626 | 1.00 | RAB9A (0.62) | RAB9AALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL30056573 | 0.95 | RAB9A (0.57) | RAB9AALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL20848110 | 0.91 | CYP3A4 (0.56) | RAB9AALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL30056612 | 0.91 | CYP3A4 (0.56) | RAB9AALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL21629650 | 0.91 | RAB9A (0.65) | RAB9AALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL21629635 | 0.91 | RAB9A (0.65) | RAB9AALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL21629559 | 0.91 | RAB9A (0.65) | RAB9AALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL20848109 | 0.91 | MAPT (0.57) | RAB9AALDH1A1HPGDKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252454-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2024-08-01 | — | — | US | claimed |
| US-20240252454-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2024-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252454-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | TFAM, POLRMT, TUFM | RAB9A 4733/4885ALDH1A1 3415/4885HPGD 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.